close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

IGC Pharma, Inc. Common Stock (NY:IGC)

0.2534 +0.0030 (+1.20%)
Official Closing Price Updated: 8:00 PM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about IGC Pharma, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression
Via ACCESS Newswire
News headline image
IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025
Via ACCESS Newswire
News headline image
IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards
Via ACCESS Newswire
News headline image
IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection
Via ACCESS Newswire
News headline image
IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation
Via ACCESS Newswire
News headline image
IGC Pharma Reports Third Quarter Fiscal 2025 Results
Via ACCESS Newswire
News headline image
IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)
Via ACCESS Newswire
News headline image
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy
Via ACCESSWIRE
News headline image
IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025
Via ACCESS Newswire
News headline image
IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon
Via ACCESS Newswire
News headline image
IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market
Via ACCESS Newswire
News headline image
IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting
Via ACCESS Newswire
News headline image
IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology
Via ACCESSWIRE
News headline image
IGC Pharma Welcomes Strategic Investment from Advisors
Via ACCESS Newswire
News headline image
IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs
Via ACCESS Newswire
News headline image
IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program
Via ACCESS Newswire
News headline image
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health
Via ACCESS Newswire
News headline image
IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances
Via ACCESS Newswire
News headline image
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences
Via ACCESS Newswire
News headline image
IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida
Via ACCESS Newswire
News headline image
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25"
Via ACCESS Newswire
News headline image
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the “Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results”
Via ACCESS Newswire
News headline image
IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection
Via ACCESS Newswire
News headline image
IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market
Via ACCESS Newswire
News headline image
IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease
Via ACCESS Newswire
News headline image
IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor
Via ACCESS Newswire
News headline image
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
Via ACCESSWIRE
News headline image
IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025
Via ACCESSWIRE
News headline image
IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment
From IGC Pharma, Inc.
Via Business Wire
News headline image
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today